Plasencia

Researchers are evaluating the safety of immunotherapy as a treatment for allergies to hymenoptera venom, including bee (Apis mellifera) and wasp (Vespula spp.) stings. This observational study aims to analyze adverse reactions to the immunotherapy as well as allergic reactions to spontaneous hymenoptera stings. The study will also assess the quality of life of patients using a questionnaire before and after the immunotherapy treatment. The study is conducted across multiple centers in Spain and involves patients aged 14 years and older who are sensitized to hymenoptera venom. Participants will receive treatment with VENOX, an allergy vaccine targeting either wasp or bee venom, depending on clinical indication. The treatment follows standard clinical practice for immunotherapy against hymenoptera venom allergy. The study plans to include approximately 120 participants and will collect data prospectively during the treatment period. During the study, researchers will monitor the occurrence of treatment-emergent adverse reactions over 12 months to evaluate safety and tolerability. Quality of life assessments will be conducted before and after immunotherapy using a questionnaire. Participant involvement includes consenting to the study, receiving immunotherapy, and undergoing follow-up evaluations to capture allergic reactions and adverse events related to the treatment.